NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE
Delisted
NBSE was delisted on the 10th of May, 2024.
33 hedge funds and large institutions have $1.05M invested in NeuBase Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less first-time investments, than exits
New positions opened: | Existing positions closed:
71% less call options, than puts
Call options by funds: $4K | Put options by funds: $14K
Holders
33
Holding in Top 10
–
Calls
$4K
Puts
$14K
Top Buyers
| 1 | +$32.9K | |
| 2 | +$31K | |
| 3 | +$5.74K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$4.88K |
| 5 |
Morgan Stanley
New York
|
+$357 |
Top Sellers
| 1 | -$14K | |
| 2 | -$6.98K | |
| 3 | -$6.08K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.41K |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5K |